• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ReWalk Robotics Ltd. filed SEC Form 8-K: Leadership Update, Other Events, Submission of Matters to a Vote of Security Holders

    9/4/24 5:39:27 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false000160796200-0000000MARLBOROUGHUS+508.251.11544.959.0123Ordinary Shares, par value NIS 0.2500016079622024-09-042024-09-04


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): September 4, 2024
     
    ReWalk Robotics Ltd.

    (Exact name of registrant as specified in its charter)
      
    Israel
    001-36612
    Not applicable
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
     
     
     
    200 Donald Lynch Blvd. Marlborough, MA
     
    01752
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154
      
    Not applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading symbol
     
    Name of each exchange on which registered
    Ordinary Shares, par value NIS 1.75
     
    LFWD
     
    NASDAQ

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    (b) Departure of Directors or Certain Officers.

    The information included below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

    Item 5.07          Submission of Matters to a Vote of Security Holders.
     
    ReWalk Robotics Ltd. (the “Company”) held its 2024 Annual Meeting of Shareholders (the “Meeting”) on September 4, 2024. An aggregate of 4,206,883 ordinary shares, or approximately 48.25% of the Company’s 8,719,265 ordinary shares issued and outstanding as of July 24, 2024, the record date for the Meeting, were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below. Proposals No. 1.a, 1.b, 2 and 7 received the requisite level of approval by shareholders. All other proposals did not receive the requisite level of support. The proposals are described in greater detail in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (“SEC”) on July 29, 2024 (the “Proxy Statement”).

    Results of the Meeting
     
    Proposal No. 1.a: To reelect Hadar Levy as a Class I director of the Board, to serve until the 2027 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999.
     
    Nominee
    For
    Against
    Abstain
    Broker Non-Votes
    Hadar Levy
    2,134,828
    94,075
    95,771
    1,882,209

    Proposal No. 1.b: To reelect Joseph Turk as a Class I director of the Board, to serve until the 2027 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999.
     
    Nominee
    For
    Against
    Abstain
    Broker Non-Votes
    Joseph Turk
    1,975,082
    253,505
    96,087
    1,882,209

    Proposal No. 2: To approve the change of the Company’s name to “Lifeward Ltd.” or such similar name as the Board of Directors shall determine and as shall be approved by the Israel Registrar of Companies, and to reflect such new name in an amendment to the Company’s Articles of Association.
     
    For
    Against
    Abstain
    3,735,838
    348,312
    122,732

    Proposal No. 3: To approve the ReWalk Robotics Ltd. 2024 Incentive Compensation Plan.
     
    For
    Against
    Abstain
    Broker Non-Votes
    432,879
    1,878,893
    12,901
    1,882,210



    Proposal No. 4: To approve the payment to the individual serving as the Company’s Chairperson of the Board from time to time of an annual fee and an annual equity grant (or cash fee in lieu of an equity grant) that are double the amounts received by other directors of the Company from time to time, effective with the date of the Meeting.
     
    For
    Against
    Abstain
    Broker Non-Votes
    422,538
    1,888,907
    13,228
    1,882,210

    Proposal No. 5: To approve a one-time grant of 28,571 restricted stock units to Larry Jasinski, the Company’s CEO, under the ReWalk Robotics Ltd. 2024 Incentive Compensation Plan.
     
    For
    Against
    Abstain
    Broker Non-Votes
    425,885
    1,885,574
    13,244
    1,882,210

    Proposal No. 6: To approve changes to the terms of the variable compensation of Larry Jasinski, the Company’s CEO.
     
    For
    Against
    Abstain
    Broker Non-Votes
    423,927
    1,885,699
    15,048
    1,882,209

    Proposal No. 7: To approve the issuance of equity compensation to Ms. Randel E. Richner, a member of the Board, in connection with the additional consulting services provided by Ms. Richner under the Consulting Agreement with Richner Consultants, LLC, a Delaware company owned by Ms. Richner.
     
    For
    Against
    Abstain
    Broker Non-Votes
    1,808,542
    426,823
    89,308
    1,882,210

    Proposal No. 8: To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.
     
    For
    Against
    Abstain
    4,002,140
    171,062
    33,679

    Proposal No. 9: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to Item 402 of Regulation S-K of the SEC, including the compensation tables and accompanying narrative disclosures.
     
    For
    Against
    Abstain
    Broker Non-Votes
    425,135
    1,884,827
    14,711
    1,882,210

    With regard to Proposal No. 9, the Compensation Committee of the Board takes note of the results of the advisory “say-on-pay” proposal and expects to consider these results and feedback received from the Company’s shareholders among the factors considered in connection with setting the compensation of the Company’s named executive officers.

    Item 8.01          Other Events.

    As previously disclosed, on June 27, 2024, Jeff Dykan, who served as a Class I director of the Board of the Company and chairperson of the Board, notified the Board that he will retire and not stand for reelection at the Meeting. The departure of Mr. Jeff Dykan from the Board became effective immediately upon closing of the Meeting.

    In addition, as previously disclosed, on June 27, 2024, the Board approved the appointment of Joseph Turk as chairperson of the Board, effective as of the Meeting.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    ReWalk Robotics Ltd.
     
     
     
     
     

    By:
    /s/ Michael Lawless
     
     
    Name:
    Michael Lawless
     
     
    Title:
    Chief Financial Officer
     
     
    Dated: September 4, 2024


    Get the next $LFWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Successfully Closes on Strategic Partnership with Oramed

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity

    3/25/26 4:10:00 PM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

    Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities,

    3/18/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

    Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

    3/13/26 8:00:00 AM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    SEC Filings

    View All

    Lifeward Ltd. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - Lifeward Ltd. (0001607962) (Filer)

    3/25/26 4:30:30 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Lifeward Ltd. (0001607962) (Filer)

    3/20/26 4:30:19 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Lifeward Ltd.

    10-K - Lifeward Ltd. (0001607962) (Filer)

    3/18/26 11:43:40 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Adar Almog

    4 - Lifeward Ltd. (0001607962) (Issuer)

    3/27/26 4:59:55 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Grant William Mark

    4 - Lifeward Ltd. (0001607962) (Issuer)

    3/27/26 4:57:20 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Reznick Yehuda

    4 - Lifeward Ltd. (0001607962) (Issuer)

    3/27/26 4:56:03 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    Lifeward Appoints Bob Marshall as Chairman of the Board

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

    12/19/25 4:05:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Names Mark Grant as New CEO

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

    5/19/25 8:30:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

    Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

    3/13/26 8:00:00 AM ET
    $LFWD
    $ORMP
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-

    3/10/26 4:15:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. Reports Third Quarter 2025 Financial Results

    Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 3

    11/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care